CSL Ltd. - ADR
CSLLY
Market Cap$148.56B
Close$
Earnings Call Q4 2023
August 15, 2023 - AI Summary
CSL delivered strong full-year results, with revenue up 31% at constant currency and NPATA of $2.6 billion, up 20%.
The CSL Behring business saw strong growth in its Ig franchise, with sales up 21%. Plasma collections reached record levels, and the company dosed its first patients with HEMGENIX, a gene therapy for hemophilia B.
CSL Seqirus achieved strong sales growth, driven by FLUCELVAX, which was up 30%. The company also signed a licensing agreement with Arcturus Therapeutics for next-generation mRNA vaccine technology.
Exclusive for Stockcircle Pro members
Sign up
$13.73
82% downside
Current Fair Value
82% downsideOvervalued by 82% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $148.56 Billion |
|---|---|
| Enterprise Value | $159.00 Billion |
| Dividend Yield | $1.325 (1.77479837867202%) |
| Earnings per Share | $1.37 |
| Beta | 0.33 |
| Outstanding Shares | 1,935,519,348 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 26.93 |
|---|---|
| PEG | 118.57 |
| Price to Sales | 5.88 |
| Price to Book Ratio | 7.64 |
| Enterprise Value to Revenue | 5.91 |
| Enterprise Value to EBIT | 24.25 |
| Enterprise Value to Net Income | 33 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.64 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About CSL Ltd.
CEO: Paul Perreault